key: cord-0702069-3nslchio
authors: Park, Mina; Pawliuk, Colleen; Nguyen, Tribesty; Griffitt, Amanda; Dix-Cooper, Linda; Fourik, Nadia; Dawes, Martin
title: Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020
date: 2021-04-08
journal: Euro Surveill
DOI: 10.2807/1560-7917.es.2021.26.14.2001506
sha: c196b80319106198a11e6bff7014e8f0440552f4
doc_id: 702069
cord_uid: 3nslchio

INTRODUCTION: Standard testing for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is based on RT-PCR tests, but detection of viral genetic material alone does not indicate ongoing infectious potential. The ability to isolate whole virus represents a better proxy for infectivity. AIM: The objective of this study was to gain an understanding of the current literature and compare the reported periods of positive SARS-CoV-2 detection from studies that conducted RT-PCR testing in addition to experiments isolating whole virus. METHODS: Using a rapid review approach, studies reporting empirical data on the duration of positive RT-PCR results and/or successful viral isolation following SARS-CoV-2 infection in humans were identified through searches of peer-reviewed and pre-print health sciences literature. Articles were screened for relevance, then data were extracted, analysed, and synthesised. RESULTS: Of the 160 studies included for qualitative analysis, 84% (n = 135) investigated duration of positive RT-PCR tests only, 5% (n = 8) investigated duration of successful viral isolations, while 11% (n = 17) included measurements on both. There was significant heterogeneity in reported data. There was a prolonged time to viral clearance when deduced from RT-PCR tests compared with viral isolations (median: 26 vs 9 days). DISCUSSION: Findings from this review support a minimum 10-day period of isolation but certain cases where virus was isolated after 10 days were identified. Given the extended time to viral clearance from RT-PCR tests, future research should ensure standard reporting of RT-PCR protocols and results to help inform testing policies aimed at clearance from isolation.

Understanding how long individuals may continue to transmit virus after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important to inform testing policies and isolation procedures required to prevent nosocomial and community spread. Numerous studies have been conducted to date to address this question; however, the literature has been predominantly represented by studies using methods based on reverse transcription-PCR (RT-PCR) tests. As RT-PCR tests detect the presence of viral genetic material and thus do not differentiate between live (or viable) and non-infective virus [1] , inferences from these results as to potential infectious periods are limited.

A more accurate proxy of infectious potential is based on the ability of whole virus to be successfully isolated and cultured in laboratory settings, with clinical confirmation of transmission where possible. While fewer studies have been conducted that have successfully isolated and cultured live virus, results from this literature have contributed to a number of reviews [2] [3] [4] [5] [6] [7] . The findings from these reviews have drawn consistent conclusions that align with previously recommended isolation strategies [8] : overall, infectious potential appears to be greatly reduced by day 10 following symptom onset of coronavirus disease [2, 7, 9] .

However, a growing concern relates to individuals who continue to test positive by RT-PCR over extended periods of time [10] [11] [12] [13] [14] [15] [16] , including those who re-test positive after an initial negative test result [10] . As RT-PCR tests of respiratory samples have been and will remain the de facto method of confirming initial and ongoing infection with SARS-CoV-2, it is important to be able to interpret positive test results that are obtained throughout the disease course, including during convalescence.

Against a backdrop of dramatically rising cases internationally, limited testing resources and public health capacity for ongoing case management, and ongoing restrictions on mobility, there is a need for as much evidence as possible to help understand the likely implication of ongoing positive tests or re-tests after cessation of the recommended period of isolation, on potential disease spread.

The purpose of this review was to conduct a rapid review of existing literature in order to directly compare the duration of potential infectivity of SARS-CoV-2 from studies that obtained measurements of the duration of infectious potential using both RT-PCR and viral isolation methods. An additional, and related, objective was to understand and be able to provide an overview of the literature at the time the review was conducted (until end of September 2020), especially given the evolving nature of the pandemic.

We conducted a rapid review of the literature using the methods outlined in the National Collaborating Centre for Methods and Tools Guidebook [17] . We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to report our rapid review [18] . We did not publish or pre-register a protocol for our review given time pressures for this information. From the available data, duration (maximums, medians or means values) was retrieved or calculated. Ethics approval was not required.

Databases of peer-reviewed and pre-print health sciences literature (Ovid MEDLINE, Embase, Google Scholar, medRxiv and arXiv) and the grey literature for reports or guidelines on discontinuation of isolation for SARS-CoV-2 from international and national public health organisations (World Health Organization, European Centre for Disease Prevention and Control, United States Centre for Disease Control websites) were searched using two search strategies: (i) terms for 'SARS-CoV-2' and 'viral clearance/shedding,' on 23 May 2020 and (ii) terms for 'SARS-CoV-2' and 'viral isolation/culture,' on 1 July 2020. The latter search was done with specific terms because there was a paucity of studies with data from viral isolation/cultures identified in the previous iteration of the search; moreover, in order to include more recently published studies, we examined other reviews, including a living evidence review, until 29 September 2020 and added relevant references to our results [1, 2, [5] [6] [7] 9] . All databases were searched from inception and searches were limited to English. Detailed information on search strategies undertaken in each database can be found in the Supplement (Appendix A). Additional studies were identified by reviewing the references of select highimpact articles, reports from reputable sources, and existing reviews. Any studies identified through other sources or contacts were manually added.

We included studies presenting primary empirical data on duration of possible infectivity of SARS-CoV-2 in human populations using respiratory samples and reported in English. Articles that did not report data on duration of potential infectiousness in text, figures or tables were excluded. Studies reporting solely on pre-symptomatic or on convalescent period durations, incubation periods, serial intervals or on results based on statistical modelling were excluded. Studies, including reviews, that used data from other investigations were excluded; where relevant studies were identified, their references were reviewed to add relevant primary studies. When duplicate study reports were identified (i.e. a pre-print and a peer-reviewed journal article), the most recent version was included. Inclusion criteria are outlined in more detail in the Supplement (Appendix B).

Titles and abstracts were screened for relevance independently by two reviewers. Full-text review was conducted independently by two reviewers for articles where relevance was not readily determined from title and abstracts, and any conflicts were resolved through consensus by the two reviewers.

A draft data extraction form was developed and trialled across multiple reviewers to develop the final version. Extracted data fields included study characteristics (first author, publication status, study type, sample size), study population characteristics (age, hospitalisation, disease severity), method of determining infectious period (viral shedding, viral isolation), type of respiratory specimen(s) collected, reported durations (minimum, mean, median, maximum), whether cases without symptoms (asymptomatic or pre-symptomatic) were reported, whether the study focused solely on duration of communicability during the convalescent phase, how measurement of duration start and end was defined, and study quality. All extracted data were reviewed by a second reviewer.

Sample size was defined as the total number of participants for whom data on communicability period was assessed. Disease severity associated with SARS-CoV-2 infection was classified according to the following definitions: mild referred to study populations reporting no symptoms or non-serious symptoms that did not require healthcare intervention, moderate severity included participants who required acute care and/or intervention, and severe disease referred to cases that required admission to the intensive care unit, critical intervention and/or resulted in death. Studies that included participants with mild, moderate and severe cases were classified as 'mixed'; otherwise, if they included cases that were mild/moderate or moderate/severe, they were categorised as the higher level of severity. Hospitalisation status was determined as described in the study. Notably, in some jurisdictions, admission to hospital appeared to be part of routine isolation policies and so this description alone was not taken as an indicator of disease severity. Studies with children were those that included participants aged 19 years or younger. Respiratory samples included those taken from the upper (naso/oro-pharyngeal, nasal, throat, or saliva swabs) or lower respiratory tract (from sputum or bronchial lavage specimens). For the purposes of this review, the start of measurement of duration is referred to as 'symptom onset' and measurement end as 'viral clearance'. The end point for measuring duration of viral isolation was the last reported day on which virus could be isolated and cultured (captured under 'other').

An adaptation of the Mixed Methods Appraisal Tool was used to assess study quality [19] . Questions were concerned with the following: (i) the study had clear research questions or objectives, (ii) the collected data allowed the study to address the stated research The PRISMA flowchart details the number of studies identified through our search and then included for analysis after screening for eligibility [18] . Table 1 Characteristics of included studies, overall and broken down by method of assessment of duration of communicability of SARS-CoV-2, March-September 2020 (n = 160) question, (iii) the research question was aimed at understanding duration of communicability, (iv) there was a complete follow-up period defined to measure duration of communicability and (v) there was clarity about when measurement of communicability period started, about sample types collected and frequency of sample collection, about how long patients were followed (until viral clearance, study end, hospital discharge, death) and about the method of assessment of communicability. Owing to the emerging nature of this topic, we did not exclude studies from our synthesis or analysis based on study quality.

All data processing and analysis was conducted using the statistical programming language R (version 4.0.0) [20] . For studies where more than one value was reported for duration (i.e. when data for multiple sample types were reported or results were presented in a stratified manner), the values corresponding to the higher duration were included for analysis. As analyses were generally aimed at identifying maximum reported durations, these values were pulled from each study and summarised. Raw data are available in Supplementary Table S1 .

We retrieved, 2,174 records from database searches and 91 additional studies from reference chaining and other sources (2,265 total), of which 1,481 remained after removing duplicate records. Of these, 1,234 were excluded in screening and 87 in full-text review as they did not report data on duration of potential infectivity, used secondary data from the literature, reported only on the convalescent period, assessed non-respiratory samples only, the full text was not accessible, or they were duplicate reports of the same study. 160 studies were included in the final synthesis. The PRISMA flowchart in Figure 1 illustrates the study selection process.

Information on study characteristics is presented in Table 1 Table 1 ). The results of the study quality assessment are included in Table 1 .

The majority of studies were conducted in Asia (n = 127, 79%), with 19 studies conducted in Europe (12%), 10 in North America (6%), two in the Middle East (1%) and two in Australia (1%) ( Table 1) .

The starting point for measuring duration was primarily symptom onset (n = 91; 57%), followed by hospital admission (n = 36; 23%), when the patient first tested positive for SARS-CoV-2 (n = 12; 8%) or other (n = 21; 13%). The end point of duration measurement for most studies was the date of a single or consecutive negative RT-PCR test (n = 114; 71%), followed by discharge/ death (n = 8; 5%), last positive test (n = 7; 4%) or other (n = 31; 19%).

At the time of writing, 26 (16%) of the studies included in this review were pre-prints and thus had not undergone peer-review. Many of the remaining studies published in peer-review journals were letters to the editor or other short communications that do not fully report their methods. There was variation in study quality in both preprints and studies published in peer-reviewed journals; roughly half of the included studies (n = 86; 54%) had two or more study quality concerns ( Table 1 ).

There were 17 studies that investigated the duration of time until viral clearance through RT-PCR tests as well as viral isolation [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . Eight other studies investigated viral isolation durations only [36, [38] [39] [40] [41] [42] [43] [44] . Supplementary Table S2 displays detailed information on each individual study. those that did, the range of Ct values with a successful isolation was 12.3-37.9.

All studies that measured the longest time to viral clearance in both RT-PCR tests and viral isolation experiments reported positive RT-PCR test results after virus was no longer able to be isolated and cultured. The median duration after symptom onset that virus was successfully isolated was 9 days (IQR: 2.25; range: 2-21), while the corresponding median value for longest duration until viral clearance by RT-PCR was 26 days (IQR: 16.8; range: 8-63) (Figure 2 ). Three studies reported successful viral isolation beyond 10 days (Figure 2 ).

We conducted a final analysis on all included studies that had measurements of maximum duration to viral clearance (n = 142). In 20 studies that successfully achieved viral isolations, viable virus could be isolated from a case across a range of 2-32 days after symptom onset; the median and mean durations of these values across studies were 10.5 days (IQR: 10) and 12.8 days (SD: 7.3), respectively. From the 134 studies with data on maximum duration of positive RT-PCR test results, the shortest reported time until viral clearance was 5 days from symptom onset, while the maximum was 95 days, with respective median and mean values of 25 days (IQR: 19) and 28.8 days (SD: 15.8) (Table 3) . 

Overview of studies that included measurements of duration to SARS-CoV-2 clearance from both RT-PCR and viral isolation experiments, March-September 2020 (n = 12) Young 

This review contributes to the evidence on the period of potential infectivity after infection with SARS-CoV-2, showing that positive detection of viral nucleic acid by RT-PCR can far exceed the duration after which viral transmission may occur. Results from this review suggest that positive RT-PCR results after day 10 following symptom onset of COVID-19 are unlikely to indicate infectiousness. The conclusions of this review are also in line with recently updated guidelines that support relying on symptoms rather than RT-PCR test results for ending isolation precautions in non-healthcare settings [45] .

Overall, results from this review concur with previous studies that also support a general 10-day isolation period. However, in reviewing the data from all studies reporting viral isolation, we identified important exceptions. The longest period that virus was isolated after symptom onset was 32 days from a hospitalised patient with severe disease [46] . A duration of 21 days was identified from a report of a single individual with mild symptoms but with significant underlying conditions including a recent heart transplant [21] . A separate case report of an individual without any significant comorbidities and also with mild disease symptoms reported viable virus until 18 days [11] . One case series of 129 hospitalised patients with moderate to severe disease, and mixed degrees of comorbidities, reported a maximum duration of viable virus of 20 days, with a median time to viral clearance in this sample of eight days [38] .

Although these exceptions may not occur frequently, they highlight the need to be cautious when COVID-19 cases are being released from isolation into high-risk settings. Previous studies have suggested that there may be differences in duration of viral viability by disease severity with cases of more severe disease potentially having longer infectious viral shedding [7, 39] . Despite such trends, the select cases highlighted herein suggest symptom presentation and disease severity do not always follow a pattern with respect to duration of viral viability. Of the studies assessing viral isolation, some also isolated and cultured virus from patients who were asymptomatic or during their convalescent disease period [21] [22] [23] [24] .

Given the prolonged detection of viral nucleic acid by RT-PCR testing, there have been suggestions to incorporate additional testing metrics when results are being used to inform release from isolation [9, 40] , such as Ct values. This would be an important and relevant qualification to current protocol especially when considering that positive tests from RT-PCR may persist for several weeks [12] [13] [14] [15] [16] 41, 47] . While the available data on RT-PCR Ct values and viral viability were inconsistent, a number of studies have reported an upper Ct limit for successful viral isolation [9, 22, [25] [26] [27] [28] 40, 41, 46] which may help inform future threshold values.

This review highlights significant heterogeneity in the content and quality of the underlying literature which limits the ability to draw robust inferences to inform isolation protocols from the available data. There was a general paucity of high-quality evidence. We identified few studies that investigated viral isolation and many of the included studies had small sample sizes, making it difficult to draw robust findings from the single subject studies. The included studies suffer from selection bias and lack of generalisability, as case reports and case series often focus on highly specific clinical populations that do not represent the majority of COVID-19 cases. Given that data were often drawn from applied clinical settings, several of the included studies did not follow participants until viral clearance or collect samples at consistent intervals throughout the communicable period. A lack of reporting standards also resulted in incomplete information on valuable metrics such as viral load and Ct values. Finally, although this was not a focus of this review, studies that are able to demonstrate clinical confirmation of transmission are needed to better understand infectivity [47] .

This study builds off of previous research by directly comparing results from all studies that measured both the maximum duration of positive RT-PCR test results and longest time to successful viral isolation, thereby adding robustness to interpreting overall findings from the literature. We have made the raw data extracted from all studies in this review available in Supplementary  Table S1 for the benefit of other research or public health groups. This research identifies improvements for future research and reporting that should enable more robust syntheses of newly emerging evidence to better inform infection control policies for SARS-CoV-2.

Understanding COVID-19: what does viral RNA load really mean?

Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases

Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature

Viral cultures for COVID-19 infectious potential assessment -a systematic review

Incidence and persistence of viral shedding in COVID-19 post-acute patients with negativized pharyngeal swab: a systematic review

Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis

The duration of infectiousness of individuals infected with SARS-CoV-2

Criteria for releasing COVID-19 patients from isolation. Geneva: WHO

Viral cultures for COVID-19 infectivity assessment. Systematic review. medRxiv

Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. medRxiv

Prolonged virus shedding even after seroconversion in a patient with COVID-19

The clinical characteristic of eight patients of COVID-19 with positive RT-PCR test after discharge

Clinical Course and Risk Factors for Recurrence of Positive SARS-CoV-2 RNA: A Retrospective Cohort Study from Wuhan, China. medRxiv

Case report: viral shedding for 60 days in a woman with COVID-19

Persistent viral RNA positivity during the recovery period of a patient with SARS-CoV-2 infection

Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia

National Collaborating Centre for Methods and Tools. Hamilton: National Collaborating Centre for Methods and Tools

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers

R: A language and environment for statistical computing

Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

SARS-CoV-2 infection in a 76-year-old man with initially negative results for nasopharyngeal swabs

Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland

Prolonged virus shedding even after seroconversion in a patient with COVID-19

SARS-CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with mild coronavirus disease

Virological assessment of hospitalized patients with COVID-2019

Viral dynamics and immune correlates of COVID-19 disease severity

Persistent viral presence determines the clinical course of the disease in COVID-19

Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient

Detection and isolation of SARS-CoV-2 in serum, urine, and stool specimens of COVID-19 patients from the Republic of Korea. Osong Public Health Res Perspect

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. medRxiv

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Repeat COVID-19 molecular testing: correlation with recovery of infectious virus, molecular assay cycle thresholds, and analytical sensitivity. medRxiv

Culturecompetent SARS-CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents

Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19

Viable SARS-CoV-2 in various specimens from COVID-19 patients

Investigation of SARS-CoV-2 outbreaks in six care homes in London

Interim guidance on duration of isolation and precautions for adults with COVID-19

Persistent SARS-CoV-2 replication in severe COVID-19. medRxiv

Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset

Analysis of factors affected the SARS-CoV-2 viral shedding time of COVID-19 patients in Anhui, China: a retrospective study. Research Square

Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva

Novel Coronavirus can be detected in urine, blood, anal swabs and oropharyngeal swabs samples. medRxiv

A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic

A case report of moderate COVID-19 with an extremely long-term viral shedding period in China

A case series of children with 2019 Novel Coronavirus infection: clinical and epidemiological features

A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis

A child with household transmitted COVID-19

A community-transmitted case of severe acute respiratory distress syndrome (SARS) due to SARS-CoV-2 in the United States

A followup study of children infected with SARS-CoV-2 from western China

A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19

A report of three COVID-19 cases with prolonged viral RNA detection in anal swabs

A severe-type COVID-19 case with prolonged virus shedding

A special case of COVID-19 with long duration of viral shedding for 49 days. medRxiv

A case of critically ill infant of coronavirus disease 2019 with persistent reduction of T Lymphocytes

A well infant with coronavirus disease 2019 with high viral load

Anal swab findings in an infant with COVID-19

Assessing viral shedding and infectivity of tears in Coronavirus Disease

Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study. medRxiv

Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster

Asymptomatic SARS-CoV-2 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for 42 days

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR

Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Clinical and epidemiological features of a family cluster of symptomatic and asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 infection

Clinical and epidemiological features of COVID-19 family clusters in Beijing

Clinical characteristics of 10 children with COVID-19 outside of Wuhan in Hubei Province. Research Square

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

Clinical characteristics of patients hospitalized with Coronavirus Disease

Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test. medRxiv

Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features and dynamics of viral load in imported and nonimported patients with COVID-19

Clinical progression of patients with COVID-19 in Shanghai

Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps

Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients

Consistent Detection of 2019 Novel Coronavirus in Saliva

Contact tracing and isolation of asymptomatic spreaders to successfully control the COVID-19 epidemic among healthcare workers in Milan (Italy). medRxiv

Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission

Coronavirus disease 2019 in pregnancy

Coronavirus Disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China

Correlation between relative nasopharyngeal virus RNA Load and lymphocyte count disease severity in patients with COVID-19

Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)

COVID-19 in 2 persons with mild upper respiratory tract symptoms on a cruise ship

COVID-19 in a designated infectious diseases hospital outside Hubei Province

Delayed clearance of SARS-CoV2 in male compared to female patients: High ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs. medRxiv

Diagnosis and management of first case of COVID-19 in Canada: lessons applied from SARS-CoV-1

Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA resting, and outcomes

Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again

Do children need a longer time to shed SARS-CoV-2 in stool than adults?

Duration of SARS-CoV-2 viral shedding during COVID-19 infection

Duration of viral detection in throat and rectum of a patient with COVID-19. medRxiv

Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient

Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study

Early risk factors for the duration of Severe Acute Respiratory Syndrome Coronavirus 2 viral positivity in patients with Coronavirus Disease

Early viral clearance and antibody kinetics of COVID-19

among asymptomatic carriers. meRxiv

Effect of convalescent plasma therapy on viral shedding and survival in patients with Coronavirus Disease

Epidemiologic features and clinical course of patients infected With SARS-CoV-2 in Singapore

Epidemiological and clinical characteristics of 26 asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 carriers

Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau

Evidence for gastrointestinal infection of SARS-CoV-2

Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (Beijing)

Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study

Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19

Factors associated with prolonged viral RNA shedding in patients with Coronavirus Disease 2019 (COVID-19)

Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection

Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia

First Case of an Infant with COVID-19 in the Middle East

First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan

First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA

First mildly ill, nonhospitalized case of Coronavirus Disease 2019 (COVID-19) without viral transmission in the United States

Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. medRxiv

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv

Hypertension and diabetes delay the viral clearance in COVID-19 patients. medRxiv

Letter to the Editor: Three cases of redetectable positive SARS-CoV-2 RNA in recovered COVID-19 patients with antibodies

Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study. medRxiv

Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study. medRxiv

Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19

Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions. medRxiv

Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China

Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

Patients with respiratory symptoms are at greater risk of COVID-19 transmission

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19)

Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19

Positive SARS-Cov-2 test in a woman with COVID-19 at 22 days after hospital discharge: A case report

Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China

Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Prolonged Viral RNA Shedding Duration in COVID-19

Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019

Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report

Rehospitalization of a Recovered Coronavirus Disease 19 (COVID-19) Child With Positive Nucleic Acid Detection

Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. medRxiv

Risk factors for viral RNA shedding in COVID-19 patients

SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection

SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standards for discharge

SARS-CoV-2 viral load in clinical samples from critically ill patients

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Sequential analysis of viral load in a neonate and her mother infected with Severe Acute Respiratory Syndrome Coronavirus 2

Seven discharged patients turning positive again for SARS-CoV-2 on quantitative RT-PCR

Severe Acute Respiratory Syndrome Coronavirus 2 Shedding by Travelers

Silent disease and loss of taste and smell are common manifestations of SARS-COV-2 infection in a quarantine facility: first report from Saudi Arabia. medRxiv

Symptomatic infection is associated with prolonged duration of viral shedding in mild Coronavirus Disease 2019: a retrospective study of 110 children in Wuhan

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients

Duration of viral shedding of discharged patients with severe COVID-19

The first infant case of COVID-19 acquired from a secondary transmission in Vietnam

The index case of SARS-CoV-2 in Scotland

The natural history and transmission potential of asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection

The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients

The time sequences of respiratory and rectal viral shedding in patients with Coronavirus Disease

Time kinetics of viral clearance and resolution of symptoms in Novel Coronavirus infection

Transmission risk of patients with COVID-19 meeting discharge criteria should be interpreted with caution

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Treatment response to Hydroxychloroquine, Lopinavir/ Ritonavir, and antibiotics for moderate COVID 19: a first report on the pharmacological outcomes from South Korea. medRxiv

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Viral dynamics in asymptomatic patients with COVID-19

Viral dynamics in mild and severe cases of COVID-19

Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19

Viral kinetics and antibody responses in patients with COVID-19. medRxiv

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Viral load of SARS-CoV-2 in clinical samples

Viral loads in throat and anal swabs in children infected with SARS-CoV-2

Virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients. medRxiv

License, supplementary material and copyright

We would like to thank Kelsey Furk and John Harding for their contributions to the development and design of this study.

MD is Chief Scientific officer at GenXys Health Care Systems; GenXys was not involved at any stage of this study. All other authors declare no conflicts of interest.

MP designed the study, conducted analyses, and wrote the first draft of manuscript. CP contributed to study design, data cleaning and analysis, and implemented the search strategy. MP, CP, TN, AG, LDC, NF and MD contributed to screening of articles, data extraction, and critical review and approval of the final manuscript.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.Any supplementary material referenced in the article can be found in the online version.